Investment Case
Why Curasight. Why uPAR. Why now.
A clinical-stage radiopharmaceutical company at a therapeutic inflection point
Curasight is building a uPAR-targeted radiopharmaceutical portfolio through two platform brands: uTRACE® for imaging and diagnostics and uTREAT® for therapeutic development. The lead glioblastoma clinical program sits within uTREAT® and currently uses 64Cu-DOTA-AE105 at imaging and dosimetry activity to generate human delivery data intended to support a separate 177Lu therapeutic product. Within uTREAT®, the next-generation systemic ligand program is a separate product path capable of generating distinct radionuclide-specific (alpha and beta) therapeutic candidates.
The investment case combines target differentiation, human imaging evidence, staged clinical execution toward therapeutic dosing, a licensed prostate imaging indication and a pipeline architecture designed to create multiple development and strategic value inflection points.
A differentiated RLT target
uPAR is associated with invasion, angiogenesis and metastasis across multiple solid tumors. Curasight is seeking to establish uPAR as a new target class for radioligand therapy.
Human target characterization
More than 500 patients have been imaged in nine investigator-initiated uPAR PET clinical trials across eight tumor types, providing a substantial human evidence base before broad therapeutic and diagnostic expansion.
Therapeutic clinical execution
The current Phase 1 glioblastoma study sits within uTREAT® and uses 64Cu-DOTA-AE105 for imaging and dosimetry activity for confirmation of local delivery, biodistribution and dosimetry. The resulting human data are intended to inform the clinical testing of a separate 177Lu therapeutic product within uTREAT®.
Multiple product paths
The portfolio separates platform, ligand, product and clinical-program levels. uTRACE® and uTREAT® are the platform brands. AE105-family and next-generation uPAR binders are ligand technologies beneath them. Specific ligand-radionuclide combinations form distinct product candidates.
Diagnostic value and partnership
uTRACE®, in addition to being a target confirmation tool for uTREAT®, has independent diagnostic and prognostic potential. The prostate cancer indication is licensed to Curium.
Intellectual property
Curasight has granted patents and pending applications across major jurisdictions through 2043. Remaining patent life varies by product, patent family and jurisdiction.
Curasight is listed on Spotlight Stock Market under ticker CURAS and traded in DKK.
Investors should review the company’s latest financial reports, risk disclosures and market announcements before making an investment decision.
